Breadcrumb

null Lucy Gilbert, MD, M.Sc., FRCOG

Investigator, RI-MUHC, Glen site

Cancer Research Program

Professor, Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, McGill University

Department of Obstetrics and Gynaecology, Division of Gynecologic Oncology, MUHC

 

Keywords

ovarian cancer • endometrial cancer • early detection • clinical trials • precision therapies • genomic solutions for diagnosis and treatment

Research Focus

I head the Women’s Health Research Unit of the MUHC, one of the most active research units in gynecologic cancer in Canada. With collaborators in the molecular genetics, computational genomics, and mechanical engineering departments at McGill University, I am principal investigator of a study that has developed a new genomic pap test called DOvEEgene (Detecting Ovarian and Endometrial cancer Early using genomics). DOvEEgene is currently being evaluated in a Phase III trial with the support of the Genomic Applications Partnership Program (GAPP), which is co-funded by Genome Canada, Génome Quebec and the McGill University Health Centre Foundation. The test uses next-generation sequencing to interrogate 28 genes involved in the development of sporadic and hereditary ovarian and endometrial cancers in women 45-75 years old. Currently, the direct costs of treating the 10,000 Canadian women diagnosed with these cancers every year is over $1 billion. It is expected that with DOvEEgene detecting these cancers in earlier stages, these expenditures could be decreased and ultimately lead to a better prognosis for patients.

I am also Director of Gynecologic Oncology at McGill University Health Centre (MUHC), a designated tertiary/quaternary care cancer centre in the province of Quebec, Canada. In 2021 I was honoured to be recognized as one of the Top 25 Women of Influence in Canada for my contribution to Women’s Health.

Research initiative
Women's Health Research Unit

Selected Publications

Click on Pubmed to see my current publications list

  • Lucy Gilbert, Ana Oaknin, Ursula A Matulonis, Gina M. Mantia-Samldone, Peter Lim, Cesar M. Castro, Diane Porvencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleem N. Morre, David M. O’Malley. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer, Gynecologic Oncology, 170: 241-247, March 2023. https://doi.org/10.1016/j.ygyno.2023.01.020

  • Yuxuan Wang, Lu Li, Christopher Douville, Joshua D. Cohen, Isaac Kinde, Karin Sundfelt, Susanne Krüger Kjær, Ie-Ming Shih, Tian-Li Wang, Robert Kurman, Simeon Springer, Janine Ptak, Maria Popoli, Joy Schaefer, Natalie Silliman, Lisa Dobbyn, Ting-Tai Yen, Maria Lycke, Kirsten Jochumsen, Bahman Afsari, Douglas Levine, Kris Jardon, Xing Zeng, Jocelyne Arseneau Lili Fu, Luis A. Diaz Jr., Rachel Karchin, Cristian Tomasetti, Kenneth W. Kinzler, Bert Vogelstein, Amanda N. Fader, *Lucy Gilbert, Nick Papadopoulos. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers, 21 March 2018, Sci. Transl. Med. 10, DOI: 10.1126/scitranslmed.aap8793, *corresponding author

  • Gilbert L, Revil T, Meunier C, Jardon K, Zeng X , Martins C, Arseneau J, Fu L, North K, Schiavi A, Ehrensperger E, Artho G, Todd L, Morris D, Ragoussis J. The Empress of Subterfuge: cancer of the fallopian tube presenting with malapropism. The Lancet, Sep 2017; 390 (10098):1003-1004.

  • Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Efrat Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González Martín, Philippe Follana, Benedict Benigno, Per Rosenberg, Lucy Gilbert, Bobbie J. Rimel, Joseph Buscema, John P. Balser, Shefali Agarwal, Ursula A. Matulonis. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, New England Journal of Medicine, October 2016, 375(22): 2154-2164. DOI: 10.1056/NEJMoa1611310.

  • Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramana-Kumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S, for the DOvE Study Group. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. March 2012; 13(3): 285-91. PMID: 22257524.